NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis $16.00 -2.53 (-13.65%) As of 08/27/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC Filings About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$15.07▼$18.3650-Day Range$10.95▼$20.9852-Week Range$8.20▼$23.40Volume20,442 shsAverage Volume50,853 shsMarket Capitalization$64.64 millionP/E RatioN/ADividend YieldN/APrice Target$41.50Consensus RatingModerate Buy Company Overview Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States. Read More Eloxx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreELOX MarketRank™: Eloxx Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 353rd out of 920 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingEloxx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEloxx Pharmaceuticals has a consensus price target of $41.50, representing about 159.4% upside from its current price of $16.00.Amount of Analyst CoverageEloxx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Eloxx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eloxx Pharmaceuticals is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEloxx Pharmaceuticals has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.82% of the float of Eloxx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEloxx Pharmaceuticals has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eloxx Pharmaceuticals has recently increased by 47.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.97 News SentimentEloxx Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for ELOX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Eloxx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.Read more about Eloxx Pharmaceuticals' insider trading history. Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOX Stock News HeadlinesGuggenheim Reaffirms "Buy" Rating for Eloxx Pharmaceuticals (NASDAQ:ELOX)August 26 at 1:24 AM | americanbankingnews.comEloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 12, 2026 | prnewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.August 28 at 1:00 AM | Banyan Hill Publishing (Ad)Eloxx’s EXACT Study Puts Exaluren in Focus for Rare Kidney Disease InvestorsJuly 1, 2026 | tipranks.comSee More Headlines ELOX Stock Analysis - Frequently Asked Questions How have ELOX shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0121 on January 22, 2026. Since then, ELOX stock has increased by 132,131.4% and is now trading at $16.00. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its earnings results on Tuesday, August, 11th. The company reported ($0.66) earnings per share for the quarter. When did Eloxx Pharmaceuticals' stock split? Shares of Eloxx Pharmaceuticals reverse split before market open on Monday, June 1st 2026.A 1-11 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did Eloxx Pharmaceuticals IPO? Eloxx Pharmaceuticals (ELOX) raised $33 million in an initial public offering (IPO) on Tuesday, June 9th 2026. The company issued 2,975,000 shares at a price of $11.00 per share. When did Eloxx Pharmaceuticals' quiet period expire? Eloxx Pharmaceuticals's quiet period expired on Monday, July 20th. Eloxx Pharmaceuticals had issued 2,975,000 shares in its IPO on June 9th. The total size of the offering was $32,725,000 based on an initial share price of $11.00. During Eloxx Pharmaceuticals' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today8/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone781-577-5300Fax908-864-4440EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Eloxx Pharmaceuticals$41.50 High Price Target$43.00 Low Price Target$40.00 Potential Upside/Downside+159.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$6.36 million Price / Sales10.16 Cash FlowN/A Price / Cash FlowN/A Book Value$11.50 per share Price / Book1.39Miscellaneous Outstanding Shares4,040,000Free Float2,991,000Market Cap$64.64 million OptionableN/A Beta-1,864.08 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ELOX) was last updated on 8/28/2026 by MarketBeat.com Staff. From Our PartnersMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredTrump’s new dollar decreeThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...Porter & Company | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
